StudyManager, Inc., a healthcare IT company and creator of StudyManager clinical trial management software (CTMS), today announced the release of Reveal version 3.1, expanding the recruitment, financial, and reporting capabilities of its clinical trial management software (CTMS) for sites and hospitals.
Expanded Business Management and Productivity Tools for Research Sites
Reveal 3.1 allows research organizations to centralize study information, organize research activities, and increase recruitment and financial performance.
Strong Market Response to Reveal and Personalized Service
StudyManager has seen a 40% increase in Reveal sales in the second half of 2010, compared to the first half of the year. Growth is expected to accelerate further in 2011, as StudyManager pairs its Reveal cloud solution with an on-premises option and continues to expand features and services. With Reveal, each customer gets a dedicated trainer who builds a training plan around the customer’s needs and objectives.
Improving the Research Site "Bottom Line"
Reveal is built on the feedback and experience of StudyManager's customers, and the company's nearly 20 years in the field. Then, Reveal's decision support tools can have a big impact on the bottom line, helping sites negotiate more favorable contracts, make enrollment course corrections, and ensure they get paid for all study activity.
Reveal features focus on helping sites centralize study information, and:
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Funding Cuts Threaten Diversity in Clinical Research
June 27th 2025In this video interview, Kyle McAllister, co-founder, CEO, Trially, discusses how recent federal funding cuts are likely to undermine research focused on underrepresented populations, and why long-term investment in community-based studies is essential to closing persistent health equity gaps.